RecruitingNot ApplicableNCT06894875
Effects of Lentil Protein Hydrolysate on Blood Pressure Control, Vascular Function and Exercise Performance
Examining the Safety and Tolerability of Lentil Protein Hydrolysate in Healthy Males and Females Whilst Exploring the Effects of a Dose Range on Blood Pressure Control and Vascular Function and Exercise Performance
Sponsor
Nuritas Ltd
Enrollment
48 participants
Start Date
Jun 24, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
Examining the safety and tolerability of Lentil Protein Hydrolysate in healthy males and females whilst exploring the effects of a dose range on blood pressure control and vascular function and exercise performance
Eligibility
Min Age: 18 YearsMax Age: 45 Years
Inclusion Criteria8
- Willing to provide written and dated informed consent to participate in the study.
- Willing and able to comply with the protocol.
- Are not on any medication, or supplements which would impact the trial in the opinions of the investigator or Sponsor.
- Male or female between 18 and 45 years of age (18.5 kg/m2 ≥ BMI < 30 kg/m2).
- Comply with ACSM guidelines for physical activity.
- Have not participated in a clinical trial within the past month and agree to not participate in another clinical trial during the study period.
- Agree to not significantly alter diet or exercise routine during the trial period.
- Willing to wear a wearable device continuously for the duration of the study
Exclusion Criteria11
- Subjects having a known allergy or hypersensitivity to any of the ingredients in the investigational products.
- Subjects with a history of alcohol and/or other drug abuse in the past year.
- Has performed strenuous exercise (rating of perceived exertion ≥ 13) ≤ 48 hours before laboratory visit (Borg, 1982).
- Consuming >14 alcoholic drinks per week or > 2 drinks/day in the 48 hours preceding a clinic visit.
- Active smokers, nicotine use or vaping
- Subjects suffering from a sleep disorder and/or who have a known history of (or was being treated for) clinical depression, eating disorder(s) or any other psychiatric condition(s) that might put the subject at risk and/or confounded the results of the study.
- Subjects with a history of being diagnosed with phenylketonuria or another disease affecting amino acid metabolism (i.e., maple syrup urine disease, etc.).
- Subjects with an elevated resting heart rate (>100 bpm) or blood pressure (systolic BP >140 mmHg or diastolic BP >90 mmHg).
- Pregnant or lactating women
- Presentation of orthostatic hypotension during the screening and familiarisation study visit
- Any condition which in the opinion of the investigator makes the participant unsuitable for inclusion.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DIETARY_SUPPLEMENTLentil protein hydrolysate
Plant protein hydrolysate
DIETARY_SUPPLEMENTPlacebo MCC micro-crystalline cellulose
Placebo MCC micro-crystalline cellulose
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06894875
Related Trials
Home-Based Exercise Programs for Fall Prevention in Parkinson Disease
NCT075907001 location
Creatine and Resistance Training in Older Adults With Mild Cognitive Impairment
NCT069481491 location
High-Energy Laser in the Conservative Treatment of Rhizarthrosis
NCT075665071 location
Sex Differences in Cold-Induced Changes in Maximal Fat Oxidation
NCT072978231 location
Vasodilator and Exercise Study for DMD (VASO-REx)
NCT062907131 location